As Investors Again Look to RNAi, Drug Developers Pull in More than $230M | GenomeWeb

Following the close of Dicerna Pharmaceuticals Series C round of financing last week, the RNAi therapeutics space has seen a dramatic increase in investor interest, with privately held companies in the field pulling in more than $100 million thus far in 2013.

Publicly traded RNAi drug firms have also been faring well, raising more than $230 million in the first part of the year through stock offerings, with the majority going to industry leader Alnylam Pharmaceuticals.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.